Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed a significant association between antigliadin antibodies (IgA and IgG) and alopecia areata severity, suggesting that serological tests could help diagnose subclinical celiac disease in these patients, with IgA and IgG showing 100% sensitivity and specificity at specific cutoff points.

This review covers the use of JAK inhibitors in treating various dermatological conditions, emphasizing their potential while noting ongoing safety concerns with oral treatments; no new clinical results are provided.

This source reports that based on international Phase 3 trial results, the JAK1/2 inhibitor baricitinib was approved in Japan in June 2022 for treating extensive alopecia areata, offering a potentially useful treatment option.

This paper reviews current and developing treatments for severe alopecia areata but reports no new clinical findings; the authors highlight the need for standardized treatment protocols.

This article reviews the role of the JAK-STAT pathway in inflammatory skin diseases and considers the therapeutic benefits of JAK inhibitors, presenting them as promising treatments but reports no new experimental results.

In this study, researchers identified unique prenatal lymphocyte features in human fetal skin, including proliferative naive T cells and memory-like T cells, which may influence antigen and allergen responses in utero and infancy.

This research focuses on alopecia areata, highlighting the psychological impact, especially of its variant alopecia areata incognita, and provides diagnostic and treatment tips, but does not report specific results.

This review discusses diagnostic strategies for pediatric hair loss, emphasizing the importance of thorough examinations and dermoscopy for accurate diagnosis, and reports no new research findings.

This review discusses current advancements in mesenchymal stem cell-based therapies for skin repair and rejuvenation, focusing on therapeutic strategies, particularly highlighting the potential of neonatal and placenta-derived MSCs, and reports no new clinical results.

Baricitinib effectively regrew hair in a woman with alopecia universalis after other treatments failed.

This review outlines the transition from simple hair follicle organoids to immune-competent microphysiological systems, addressing limitations in replicating native hair follicle immune features and discussing their applications in disease modeling and regenerative medicine.

This review discusses the role of JAK inhibitors in treating atopic dermatitis, alopecia areata, and vitiligo, highlighting their effectiveness and safety considerations but stressing the need for further research on long-term safety and patient selection.

This study found that individualized homeopathic medicine can significantly improve outcomes in patients with alopecia areata, including complete hair regrowth and reduced SALT scores within 5 to 12 months, without relapse, and shows promise for alopecia universalis through targeted miasmatic and constitutional remedies.

This study evaluated baricitinib 4 mg treatment in severe to very severe alopecia areata, reporting significant scalp hair regrowth by Week 52, especially in short-duration episodes, suggesting treatment should continue for at least a year before assessing failure.

This case report described a five-year-old girl with alopecia areata totalis who experienced significant hair regrowth after receiving dental rehabilitation for extensive untreated caries and chronic oral infection, suggesting a possible link between chronic oral infection and alopecia areata.

This study provides a framework for understanding different types of alopecias based on immune privilege collapse at specific follicular sites, revealing distinct patterns in immune effector programs and stromal influences depending on the alopecia type.

In this quasi-experimental study, 24-week tofacitinib treatment significantly improved hair regrowth in South Asian patients with alopecia areata, but a high relapse rate post-withdrawal signals the need for continuous treatment strategies.

This case report highlights significant improvement in a patient with severe alopecia areata who responded well to ivarmacitinib after a suboptimal response to another JAK inhibitor, tofacitinib, suggesting ivarmacitinib as a potential alternative for tofacitinib-refractory cases.

This review discusses the molecular mechanisms and therapeutic effectiveness of Janus Kinase Inhibitors for inflammatory skin diseases, suggesting these inhibitors have a rapid onset and favorable safety profile compared to conventional treatments.

This review discusses current knowledge of keratinocyte stem cell dynamics, including their regenerative roles and potential applications beyond wound healing, but presents no new clinical findings.

This study highlights how combining genetic and environmental risk assessments could advance early screening and personalized prevention for vitiligo, given its genetic complexity and environmental interactions.

This study identified a four-gene loop as a non-invasive biomarker that selectively activates in alopecia areata, providing a precise target for JAK inhibitor treatments.

This review reports that hair follicles are dynamic neuro-immuno-endocrine organs with intrinsic signaling pathways, which play a crucial role in hair disorders like alopecia. It highlights emerging regenerative approaches targeting these pathways for hair restoration.

This review highlights recent advancements in understanding and treating alopecia, emphasizing genetic and immune factors involved in different forms, and discusses emerging therapies such as gene-editing and exosome-based treatments, though achieving complete hair regrowth remains a challenge.

This review discusses the potential of small extracellular vesicles (sEVs) as next-generation therapeutics, noting their ability to overcome biological barriers and modulate cellular environments for various diseases.

This case report presents the first instance of a pediatric alopecia areata patient switching from baricitinib to ritlecitinib, demonstrating favorable clinical outcomes, suggesting a potential new treatment pathway for children with severe cases of this condition.

This review synthesizes recent research to propose a precision framework for treating androgenetic alopecia and alopecia areata based on genetic insights and pathway biology, highlighting the roles of androgen-receptor signaling, immune dysregulation, and emerging therapies like regenerative medicine and AI-assisted diagnostics.

In this prospective cohort, baseline severity, disease activity, and relapse history were identified as key factors influencing response and recurrence in alopecia areata, suggesting that implementing standardized assessments could enhance risk stratification and personalized care approaches.

The abstract does not provide any specific research findings or results, but rather serves as a promotional description for IP Innovative Publication Pvt Limited, highlighting their services and publication offerings in medical journals and related fields from Delhi, India.

This review discusses the role of immune cells in the pathogenesis of alopecia areata and highlights emerging immunomodulatory strategies and novel therapeutic targets aimed at offering more effective and durable treatments for this autoimmune hair loss disorder.